STIM1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1429965	0.83	11/20
SCHEMBL1430047	0.65	11/20
SCHEMBL7923	0.54	11/20
SCHEMBL1430097	0.54	11/20
SCHEMBL722456	1.00	9/20
SCHEMBL722661	1.00	9/20
SCHEMBL181689	0.85	9/20
SCHEMBL1429925	0.64	9/20
SCHEMBL1429953	0.62	9/20
SCHEMBL7734	0.48	9/20
SCHEMBL721220	0.69	8/20
SCHEMBL1427395	0.66	8/20
SCHEMBL720496	0.64	8/20
SCHEMBL182078	0.64	8/20
SCHEMBL1430338	0.63	8/20
SCHEMBL1430031	0.62	8/20
SCHEMBL182143	0.58	8/20
SCHEMBL1430051	0.80	7/20
SCHEMBL182731	0.66	7/20
SCHEMBL440892	0.61	7/20

Clinical trials — most relevant to STIM1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Can Calcium Ionophore Application Enhance the ICSI Outcomes in Severe Male Factor Infertility?	PHASE2/PHASE3	UNKNOWN
The Re-Prosper HF Study	PHASE2/PHASE3	COMPLETED
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction	PHASE2	ACTIVE_NOT_RECRUITING
Lovaza's Effect on the Activation of Platelets	PHASE2	COMPLETED
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.	PHASE2	NOT_YET_RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)	PHASE2	COMPLETED
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain	PHASE2	COMPLETED
S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)	PHASE1	COMPLETED
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)	PHASE1	COMPLETED
Study of STIM1 Membrane Expression	nan	RECRUITING
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study)	nan	COMPLETED
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)	nan	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines	nan	UNKNOWN
Evaluation of A Clinical Diagnostic Test for CRDS	nan	RECRUITING
Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders	nan	UNKNOWN
New Transporting Solution in Parathyroid Allotransplantation	nan	UNKNOWN
How Secreted-embryo-derived Trypsin Initiates, Maintains and Terminates Ca2+ Signals in Uterine Epithelial Cells	nan	COMPLETED
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life	nan	COMPLETED
Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy	nan	UNKNOWN
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure	nan	UNKNOWN
Treatment of Chronic Lymphocytic Leukemia	nan	UNKNOWN
Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments	nan	RECRUITING
The Prevalence of RYR1-related Disease	nan	NOT_YET_RECRUITING
Telitacicept in the Treatment of Pediatric IgA Vasculitis-Associated Nephritis	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a STIM1 binder may also engage these)

Protein	Name	Similarity
P84903	—	1.000	P84903 →
Q58CP9	—	1.000	Q58CP9 →
P70302	—	1.000	P70302 →
P83093	—	1.000	P83093 →
STIM2	Stromal interaction molecule 2	0.999	landscape →
Q1LYM3	—	0.997	Q1LYM3 →
O35711	—	0.997	O35711 →
G5EF60	—	0.996	G5EF60 →
Q7Z3E5	—	0.996	Q7Z3E5 →
Q69ZS8	—	0.996	Q69ZS8 →
Q17QK1	—	0.996	Q17QK1 →
Q5FWS6	—	0.995	Q5FWS6 →
Q8ND30	—	0.995	Q8ND30 →
Q69ZZ6	—	0.995	Q69ZZ6 →
Q3UB74	—	0.995	Q3UB74 →
A0JMA8	—	0.994	A0JMA8 →
P28700	—	0.994	P28700 →
Q9BXL7	—	0.994	Q9BXL7 →
Q8R310	—	0.994	Q8R310 →
Q9Y3R5	—	0.994	Q9Y3R5 →
Q5XG48	—	0.994	Q5XG48 →
Q8SWR2	—	0.994	Q8SWR2 →
Q5PRF9	—	0.994	Q5PRF9 →
Q95RG8	—	0.994	Q95RG8 →
A9C3W3	—	0.994	A9C3W3 →
Q7T0S7	—	0.994	Q7T0S7 →
Q2HJE1	—	0.993	Q2HJE1 →
Q80XS6	—	0.993	Q80XS6 →
PTPN13	Tyrosine-protein phosphatase non-receptor type 13	0.993	landscape →
Q9DDT2	—	0.993	Q9DDT2 →